Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZF68E)

Drug Name

Ascrolimus Drug Info

Synonyms

A-86281; ABT-281; ZK-248258

Indication

Disease Entry	ICD 11	Status	REF
Psoriasis vulgaris	EA90	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting FK506-binding protein (FKBP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
FK-505	DMGROQP	Hyperuricaemia	5C55.Y	Phase 2	[3]
Timcodar dimesilate	DMDJLX7	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[4]
T-506	DM7XGJY	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. Transplantation. 2014 Mar 27;97(6):636-41.
2	Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995 Dec;17(6):584-91.
3	Prevention of Cardiac Hypertrophy by Calcineurin Inhibition. Circulation Research. 1999; 84: 623-632.
4	Analysis of FK506, timcodar (VX-853) and FKBP51 and FKBP52 chaperones in control of glucocorticoid receptor activity and phosphorylation. Pharmacol Res Perspect. 2014 December; 2(6): e00076.
5	EP patent application no. 0831812, Methods and compositions for stimulating neurite growth.